Table 1.

Characteristics, treatment, and clinical outcomes in all patients with diffuse large B cell lymphoma (DLBCL) and a subgroup of DLBCL patients planned to receive autologous stem cell transplantation (ASCT)*

	No. of DLBCL patients
Characteristics	total (n = 75)	planned to receive ASCT (n = 24)
Sex (male/female)	42/33	12/12
Age (years; median, IQR)	61 (47-71)	50 (41-57)
Ann Arbor III & IV	61	21
High LDH	57	21
ECOG≥2	26	11
>1 extranodal presentation	37	12
Bulky disease	28	11
Ki-67 ≥ 80%	31	8
Ki-67 ≥ 90%	18	7
B symptoms	37	15
IPI≥2	64	20
Age-adjusted IPI≥2	-	18
R-IPI poor risk	45	12
R-DA-EPOCH cycles (median, IQR)	6 (6-8)	7 (6-7)
ASCT transplantation	17	17
CD34+ cells mobilized with EPOCH	-	18/21†
Irradiation	7	2

*Abbreviations: IQR – interquartile range; LDH – lactate dehydrogenase; ECOG – Eastern Cooperative Oncology Group; B symptoms – fever, weight loss, and night sweats; IPI –International Prognostic Index; R-IPI – revised IPI; R-DA-EPOCH – rituximab plus dose-adjusted regimen combining etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin.

^†Three patients planned to receive ASCT died prior to stem cell mobilization.